Atlas Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Clinical trial NCT00502294 · WITHDRAWN

Trial details

NCT number
NCT00502294
Sponsor
Facet Biotech
Status
WITHDRAWN
Phase
Phase 3
Study type
INTERVENTIONAL
Intravenous Steroid-Refractory Ulcerative Colitis
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.